Meloxicam Safety in Cats Long Term

Colleague,

This is a critical topic in feline medicine, fraught with regulatory differences and a need for precise patient selection. Here is my breakdown of meloxicam use in cats for chronic OA pain.

Regulatory & Dosing Landscape

The primary point of confusion stems from differing labels. In the United States, the FDA label for Metacam® (meloxicam) oral suspension carries a black box warning stating it is contraindicated for repeated use in cats. The only approved use is a single, one-time subcutaneous injection for perioperative pain.

Conversely, in Europe, Australia, and Canada, the same oral liquid is approved for long-term alleviation of pain associated with chronic musculoskeletal disorders. The standard protocol is a one-time oral loading dose of 0.1 mg/kg, followed by a chronic maintenance dose of 0.05 mg/kg PO q24h.

Any long-term oral use in the US is therefore off-label and requires a frank discussion with the owner about the risks and the FDA's position.

Evidence for Long-Term Safety

The pharmacokinetic rationale for the US warning is sound: cats have deficient UGT1A6-mediated glucuronidation, leading to a prolonged meloxicam half-life (~24 hours). This creates a risk of drug accumulation and subsequent nephrotoxicity, especially in a state of dehydration or hypoperfusion.

However, several long-term studies (e.g., Gowan et al., 2011; Gunew et al., 2008) have demonstrated that low-dose (≤0.05 mg/kg/day) meloxicam can be used with a reasonable margin of safety in carefully selected and monitored cats. The key is patient selection: the cats in these studies were healthy, well-hydrated, and normotensive at baseline. The principle is to always use the lowest effective dose (LED), which may be as low as 0.025 mg/kg q24h or 0.05 mg/kg every other day for some individuals.

Monitoring Protocol & Contraindications

If proceeding with off-label use, a strict protocol is non-negotiable:

Baseline: Chemistry panel (including SDMA), CBC, and a full urinalysis. The patient must have a USG >1.035 and be non-azotemic (IRIS Stage 1).

Hydration Status: The cat must be confirmed to be well-hydrated with normal blood pressure.

Recheck: Re-evaluate renal values (creatinine, SDMA) and hydration 10-14 days after initiation, then every 3-6 months if stable.

Owner Education: Owners must be instructed to cease medication and contact you immediately if they observe anorexia, vomiting, lethargy, or polyuria/polydipsia.

Absolute contraindications:
* Pre-existing renal disease (IRIS Stage 2 or higher)
* Dehydration, hypotension, or hypovolemia
* Concurrent use of corticosteroids (high GI ulceration risk) or other nephrotoxic drugs (e.g., aminoglycosides).

Be especially cautious in cats on diuretics and/or ACE inhibitors for cardiac disease (the "triple whammy" for renal perfusion).

Alternatives When Risk is High

If a cat is not a suitable candidate for an NSAID, we have excellent, safer alternatives:
* Frunevetmab (Solensia): This is the preferred first-line choice for cats with comorbidities, especially CKD. As a monoclonal antibody against Nerve Growth Factor (NGF), it is not metabolized by the kidneys or liver, avoiding the common toxicity pathways. Its safety profile in cats with CKD is excellent.
* Robenacoxib (Onsior): While still an NSAID, its pharmacokinetic profile is more favorable. It has a very short half-life in feline blood (<2 hours) and is considered "tissue-selective," concentrating at the site of inflammation. This rapid clearance may provide a wider safety margin for the kidneys compared to meloxicam's 24-hour half-life. Note that long-term use is also off-label in the US.
* Gabapentin: A good adjunctive for OA pain, particularly if a neuropathic component is suspected. It is renally excreted, so the dose may need to be reduced in azotemic patients, but it is not directly nephrotoxic. Sedation is the primary dose-limiting side effect.

In summary, long-term meloxicam can be a valid tool, but only for the right patient with rigorous monitoring. For any cat with questionable renal function or on concurrent risky medications, frunevetmab is the superior choice from a pharmacologic safety standpoint.

Nadia will be the authority on the specific pharmacology and regulatory status, but I can speak to the clinical decision-making and patient management side of things. This is a frequent and challenging issue, especially in our aging feline population.

My primary concern with any long-term NSAID use in cats is managing the risk to the kidneys and GI tract. Patient selection is everything. Before I would even consider chronic low-dose meloxicam, I require a thorough baseline assessment: a full chemistry panel including SDMA, a CBC, a complete urinalysis (especially a USG), and a blood pressure measurement.

Contraindications: I would not use chronic meloxicam in any cat with:
* Pre-existing azotemic renal disease (IRIS Stage 2 or higher).
* Inappropriately concentrated urine (USG <1.035) in the face of normal hydration.
* Proteinuria that can't be attributed to another cause.
* A history of GI ulceration or significant chronic enteropathy.
* Concurrent use of corticosteroids or other NSAIDs.
* Hypotension or dehydration.

Monitoring Protocol: If a cat is a suitable candidate (e.g., stable, non-azotemic, well-hydrated), my monitoring protocol is strict. I recheck renal values (BUN, creatinine, SDMA) and a urinalysis 10-14 days after initiation. If stable, I then recheck every 3-6 months, depending on the patient's age and overall stability. I counsel owners extensively that any episode of anorexia, vomiting, or dehydration is a trigger to immediately stop the drug and contact us.

Alternatives: Frankly, with the advent of monoclonal antibody therapy, my reliance on chronic NSAIDs for feline OA has dropped dramatically.
* Solensia (frunevetmab): This is now my first-line recommendation for OA pain in cats, especially those with or at risk for CKD. Its targeted mechanism of action against Nerve Growth Factor (NGF) avoids the renal and GI pathways affected by NSAIDs, making it a much safer long-term option for our fragile patients.
* Gabapentin: An excellent adjunctive agent. While its efficacy as a sole analgesic for OA is debated, it's very safe, can help with comorbid anxiety or neuropathic pain, and improves quality of life through mild sedation and anxiolysis.
* Robenacoxib (Onsior): While also an NSAID, it is more COX-2 selective. The label is for short-term use, but it's an alternative. The same rigorous screening and monitoring protocols apply. It doesn't eliminate the risk, so Solensia remains my preference for high-risk patients.

In summary, while there's a place for carefully-managed, off-label low-dose meloxicam in select, healthy cats, the risks are significant. Solensia has largely replaced it as the standard of care for chronic management in my practice.

Confidence: High